NICE backs Tobi Podhaler and Colobreathe for NHS use

Both the Tobi Podhaler (tobramycin) from Novartis and Colobreathe (colistimethate sodium) received backing to treat people with cystic fibrosis who have chronic pulmonary infection caused by Pseudomonas aeruginosa in final guidance published by the National Institute for Health and Clinical Excellence (NICE).

Read the original story which was published on 27th March 2013.

Leave a Reply